The numbers, to scale
Medicaid amount reimbursed, before rebates, all four quarters. Source: CMS State Drug Utilization Data 2025, updated July 13, 2026.
CMS national totals for the same products, before rebates.
Every state (52), most spending first
| State | Medicaid paid | Share | Per Rx |
|---|---|---|---|
| California | $3,408,469,560 | 28.8% | $1,103 |
| Pennsylvania | $930,297,846 | 7.9% | $1,103 |
| New York | $929,537,839 | 7.9% | $1,139 |
| Michigan | $672,068,485 | 5.7% | $1,105 |
| North Carolina | $570,027,314 | 4.8% | $1,177 |
| Ohio | $400,484,330 | 3.4% | $942 |
| Massachusetts | $396,686,197 | 3.4% | $994 |
| Wisconsin | $320,727,766 | 2.7% | $1,060 |
| Illinois | $300,767,028 | 2.5% | $1,043 |
| Missouri | $283,188,593 | 2.4% | $993 |
| Minnesota | $255,306,584 | 2.2% | $1,107 |
| Kentucky | $237,995,148 | 2.0% | $868 |
| Louisiana | $222,629,444 | 1.9% | $967 |
| Virginia | $221,458,721 | 1.9% | $974 |
| Indiana | $203,229,705 | 1.7% | $1,070 |
| Connecticut | $199,895,862 | 1.7% | $1,146 |
| Texas | $172,658,661 | 1.5% | $1,003 |
| New Jersey | $148,512,547 | 1.3% | $897 |
| Tennessee | $142,724,727 | 1.2% | $1,050 |
| Maryland | $141,561,049 | 1.2% | $953 |
| Florida | $127,288,312 | 1.1% | $954 |
| Colorado | $126,201,892 | 1.1% | $1,026 |
| Arizona | $93,696,063 | 0.8% | $1,002 |
| West Virginia | $88,074,952 | 0.7% | $927 |
| Iowa | $87,363,092 | 0.7% | $987 |
| Oklahoma | $81,747,114 | 0.7% | $993 |
| Washington | $79,699,406 | 0.7% | $717 |
| Nevada | $77,127,780 | 0.7% | $1,090 |
| Alabama | $70,096,913 | 0.6% | $977 |
| Mississippi | $69,811,109 | 0.6% | $1,132 |
| Oregon | $65,931,413 | 0.6% | $906 |
| South Carolina | $64,914,990 | 0.5% | $997 |
| New Mexico | $64,105,089 | 0.5% | $989 |
| Kansas | $52,144,646 | 0.4% | $1,025 |
| Puerto Rico | $51,761,430 | 0.4% | $1,062 |
| Georgia | $50,632,983 | 0.4% | $853 |
| Rhode Island | $48,818,676 | 0.4% | $1,046 |
| Idaho | $45,388,950 | 0.4% | $988 |
| Maine | $38,869,770 | 0.3% | $933 |
| New Hampshire | $37,487,064 | 0.3% | $1,082 |
| Nebraska | $35,608,112 | 0.3% | $954 |
| Hawaii | $33,844,809 | 0.3% | $1,111 |
| Utah | $28,186,421 | 0.2% | $1,012 |
| District of Columbia | $22,047,712 | 0.2% | $794 |
| Montana | $21,974,228 | 0.2% | $967 |
| Alaska | $21,661,612 | 0.2% | $933 |
| Delaware | $20,132,167 | 0.2% | $362 |
| Arkansas | $18,846,808 | 0.2% | $784 |
| Vermont | $18,477,720 | 0.2% | $1,077 |
| South Dakota | $15,371,144 | 0.1% | $990 |
| North Dakota | $3,591,388 | 0.0% | $614 |
| Wyoming | $2,232,784 | 0.0% | $964 |
"Medicaid paid" is CMS's Medicaid Amount Reimbursed; "Per Rx" divides it by the state's prescriptions. Before rebates. All 52 rows, with every column, are in the CSV and JSON.
How the number is computed
Sum of "Medicaid Amount Reimbursed" across all four quarters of 2025, fee-for-service and managed care, for every GLP-1 product NDC. The national figure is CMS's national row (state code XX).
Included
- Products: Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda, Liraglutide (generic), Byetta, Bydureon, Exenatide (generic), Adlyxin.
Excluded
- Insulin combinations: Soliqua (insulin glargine and lixisenatide); Xultophy (insulin degludec and liraglutide).
- The non-Medicaid share of reimbursement (in the export as total_reimbursed_usd).
- Rows CMS suppressed for privacy.
Read it with care
- Reimbursement is what Medicaid paid pharmacies, before the manufacturer rebates states receive; CMS does not publish net cost per drug.
- CMS suppresses any row with fewer than 11 prescriptions; those rows count as zero here, so small states and small products are undercounted slightly.
- Totals reflect state program size as much as use: no per-enrollee rate is published in this dataset.
- State figures are as reported by the states and can be revised by CMS.
Receipts
2 sources · read October 4, 2026
- 01read
497 national and 11,913 state rows for the GLP-1 products listed in the method.
CMS, State Drug Utilization Data 2025 (data.medicaid.gov), updated July 13, 2026 - 02read
Amounts are reimbursements before rebates; counts under 11 are suppressed.
CMS, State Drug Utilization Data: about the data
Cite this
Free to reuse under CC BY 4.0: quote the number, credit PriceTracker GLP-1 with a link, and name the federal source. The underlying records are public; our counts, matching and files are the work you are crediting.
PriceTracker GLP-1. (2026, October 4). Medicaid GLP-1 spending by state, 2025 [Data set]. Based on Centers for Medicare & Medicaid Services data, cms data updated July 13, 2026. https://pricetrackerglp1.com/data/medicaid-glp1-spending-by-state
<p>State Medicaid programs reimbursed $11.8 billion for GLP-1 drugs in 2025 before rebates, California the most at $3.4 billion, according to CMS State Drug Utilization Data updated July 13, 2026. Source: <a href="https://pricetrackerglp1.com/data/medicaid-glp1-spending-by-state">PriceTracker GLP-1</a> (CC BY 4.0).</p>
https://pricetrackerglp1.com/data/medicaid-glp1-spending-by-state.csv https://pricetrackerglp1.com/data/medicaid-glp1-spending-by-state.json